Member Info for Sangijuelas1

Check out all the tiny sells. Some serious price control going on

Should see US Tils back over 2.60 today

Good summary on how Biogen decision will reinvigorate undervalued biotech stocks

https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKCN2DJ2LW

77p to buy

Tils is probably going to bounce today as well from the Biogen effect

I don't think people here get the impact of the Biogen decision.
It's going to give a boost to pharma across the board

Meanwhile most US Biotech’s getting ready to fly again

Except of course LBPS

That Spac deal has ****ed us cos everyone has now turned against Spacs and their targets

US Biotech’s flying.

Tils premarket 88p

I came on here to see what was going on and whether to invest and just found a load of conspiracy theory nut jobs.

Think I will give it a miss if that's the calibre of investor the stock attracts.

I was looking at a company called Trackwise. They have informed investors that they have multiple NDAs in place so I think Avacta would say if they

Surescreen got all that FT coverage as well when they launched. Weird

Maybe the confident talk about developing Blautix in house is a negotiating tactic as they have been getting low ball bids to develop it.

From February that I don't remember seeing before

https://www.google.com/amp/s/seekingalpha.com/amp/article/4406479-4d-pharma-impressive-immuno-oncology-data

This should be of interest given that it's anti cd3 like Foralumab. The article is a bit on the overly positive side as there are still some doubts about the data but there will be more pressure for approval given that the Biogen drug was approved.

https://www.healthline.com/diabetesmine/teplizumab-new-drug-to-prevent-type-1-diabetes

Graphcore news
https://www.electronicsweekly.com/news/business/nhn-adopts-graphcore-ipu-pods-2021-06/

Bit annoying that you have to pay ShareSoc to watch the presentation

I mean dosing in a P2 trial Cloudy.

I am not talking about the compassionate use case. The company is not going to get an approval or proof of concept based on 1 patient being dosed.

Good luck to you if you do believe that.

It's not emergency use authorisation it's expanded access.

I don't think they will start dosing this year as they need 6 months of data in mice and then FDA go ahead.

Should be early next year.

Bluebelly, please get real. How the hell can Tils be next to get approval for Alzheimers?

It has taken Biogen 5 year to get where they are now.
There are many promising therapies going through trials and Tils will need to get safety data before they can even get started.

Do you get the whole drug trial process thing and the kind of time frames in play?

It is giving a boost to pharma across the board. Most relevant is Provention Bio with Teplizumab which is anti CD3 and if they are approving Biogen on shaky grounds might make Teplizumab approval more likely with decision due next month.

Foralumab is licensed from Novimmune